AdvanCell strengthens cancer drug pipeline with $112m Series C funding
AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapy, has successfully completed an oversubscribed $112 million Series C funding round. The investment, co-led by ... Read More
Telix Pharmaceuticals advances prostate cancer treatment with successful TLX592 study
Telix Pharmaceuticals Limited (ASX: TLX) has announced the successful completion of the CUPID Phase I dose escalation study of TLX592, marking a significant advancement in ... Read More